These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34270458)

  • 1. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries.
    Nsanzimana S; Gupta A; Uwizihiwe JP; Haggstrom J; Dron L; Arora P; Park JJH
    Am J Trop Med Hyg; 2021 Jul; 105(3):561-563. PubMed ID: 34270458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.
    He Q; Mao Q; Zhang J; Bian L; Gao F; Wang J; Xu M; Liang Z
    Front Immunol; 2021; 12():669339. PubMed ID: 33912196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings.
    Teerawattananon Y; Anothaisintawee T; Pheerapanyawaranun C; Botwright S; Akksilp K; Sirichumroonwit N; Budtarad N; Isaranuwatchai W
    PLoS One; 2022; 17(1):e0261930. PubMed ID: 35015761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine trials: The potential for "hybrid" analyses.
    Fleming TR; Nason M; Krause PR; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Aug; 18(4):391-397. PubMed ID: 34041932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward.
    Lawal L; Aminu Bello M; Murwira T; Avoka C; Yusuf Ma'aruf S; Harrison Omonhinmin I; Maluleke P; Tsagkaris C; Onyeaka H
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034457. PubMed ID: 35240908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sars-Cov-2 virus and vaccination; biological and statistical framework.
    Arslan F; Ankaralı H
    Expert Rev Vaccines; 2021 Sep; 20(9):1059-1063. PubMed ID: 34365880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa.
    Reddy KP; Fitzmaurice KP; Scott JA; Harling G; Lessells RJ; Panella C; Shebl FM; Freedberg KA; Siedner MJ
    Nat Commun; 2021 Oct; 12(1):6238. PubMed ID: 34716349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ensuring the global COVID-19 vaccine equity: Universal vaccine access strategy in the context of low and-middle-income countries.
    Parray AA; Yadav UN; Das A; Ali AM; Mollick S; Saha S; Mistry SK
    Glob Public Health; 2022 Apr; 17(4):614-621. PubMed ID: 35050840
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Ogar CK; Quick J; Gilbert HN; Vreman RA; Mantel-Teeuwisse AK; Mugunga JC
    Drug Saf; 2023 Apr; 46(4):357-370. PubMed ID: 36811813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
    Sharma D
    Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why COVID vaccines are so difficult to compare.
    Ledford H
    Nature; 2021 Mar; 591(7848):16-17. PubMed ID: 33623151
    [No Abstract]   [Full Text] [Related]  

  • 17. Considerations on the clinical development of COVID-19 vaccine from trial design perspectives.
    Jiang Z; Wang X; Xia J
    Hum Vaccin Immunother; 2021 Mar; 17(3):656-660. PubMed ID: 32991223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs.
    Nhamo G; Chikodzi D; Kunene HP; Mashula N
    Glob Public Health; 2021 Mar; 16(3):319-339. PubMed ID: 33317389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccines for low- and middle-income countries.
    Choi EM
    Trans R Soc Trop Med Hyg; 2021 May; 115(5):447-456. PubMed ID: 33733663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hard choices: Ethical challenges in phase 1 of COVID-19 vaccine roll-out in South Africa.
    Moodley K; Blockman M; Pienaar D; Hawkridge AJ; Meintjes J; Davies MA; London L
    S Afr Med J; 2021 Mar; 111(6):554-558. PubMed ID: 34382565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.